Su Han Lum

Su Han Lum

Auto-generated profile, based on publicly available information

Su Han Lum

Translational & Clinical Research Institute Newcastle University Newcastle upon Tyne UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Blood
Verified
Journal Article
Closed access
RCRobert Chiesa
Robert Chiesa
JWJunfeng Wang
Junfeng Wang
HBHenric-Jan Blok
Henric-Jan Blok
SHSheree Hazelaar
Sheree Hazelaar
BNBenedicte Neven
Benedicte Neven
MSMary A. Slatter
Mary A. Slatter
Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, but the indication to transplant remains controversial. We performed a retrospective multicenter study of 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018. We studied 635 children (aged 1 antigen mismatch. Choice of conditioning regimen did not influence OS or EFS. In summary, we report an excellent outcome after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages. Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome. Transplantation should be strongly considered at a younger age and particularly in the presence of a well-matched donor.

6 April 2017 in Blood
Verified
Journal Article
Open access
PDF file
PHPrashant Hiwarkar
Prashant Hiwarkar
PAPersis Amrolia
Persis Amrolia
PSPonni Sivaprakasam
Ponni Sivaprakasam
SLSu Han Lum
Su Han Lum
HDHemalatha Doss
Hemalatha Doss
RWRobert Wynn
Robert Wynn
Cidofovir is preemptively used for controlling adenoviremia and preventing disseminated viral disease in hematopoietic cell transplant (HCT) recipients but does not lead to resolution of viremia without T-cell immune-reconstitution. The lipid-conjugated prodrug of cidofovir, brincidofovir, has improved oral bioavailability and achieves higher intracellular concentrations of active drug. We present retrospective multicenter data comparing the kinetics of viremia and toxicities following preemptive treatment with and brincidofovir in children and adolescents diagnosed with HCT-related adenoviremia. Forty-one episodes (18 = brincidofovir; 23 = cidofovir) of antiviral therapy were observed in 27 patients. The 2 groups had comparable immune-reconstitution and viral burden. Major (≥2 log-reduction in 2 weeks; n = 13) and minor (≥1 to ≤2 log-reduction in 2 weeks; n = 2) virological responses were observed in 15 (83%) brincidofovir episodes compared to only 2 (9%) major virological responses with cidofovir (P < .0001). Brincidofovir mediated major responses in 9 of 11 cidofovir-unresponsive patients and resulted in complete responses (CR) despite significant lymphopenia (Brincidofovir vs cidofovir; CR = 13 (80%) vs 8 (35%); median lymphocyte count = 320/μl vs 910/μl; P < .05). One patient experienced abdominal cramps and diarrhea necessitating interruption of brincidofovir and none developed nephrotoxicity with brincidofovir. Thus, brincidofovir is well-tolerated and highly efficacious in controlling adenoviremia during the lymphopenic phase of HCT.

27 June 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
UCUniversiti Malaya Medical Centre
Universiti Malaya Medical Centre
MAMohamad Shafiq Azanan
Mohamad Shafiq Azanan
SGSayyidatul Syahirah Abd Ghafar
Sayyidatul Syahirah Abd Ghafar
LOLixian Oh
Lixian Oh
KLKee Hie Lau
Kee Hie Lau
PHPierre Hainaut
Pierre Hainaut

15 September 2016 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
SLSu Han Lum
Su Han Lum
ATAndrew Turner
Andrew Turner
MGMalcolm Guiver
Malcolm Guiver
DBDenise Bonney
Denise Bonney
TMTimorthy Martland
Timorthy Martland
RWRobert PROF R Paed Wynn
Robert PROF R Paed Wynn

20 February 2017 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SLS H Lum
S H Lum
WMW P Miller
W P Miller
SJSimon Jones
Simon Jones
KPK Poulton
K Poulton
WOW Ogden
W Ogden
RWR F Wynn
R F Wynn

3 June 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
REReem Elfeky
Reem Elfeky
GLGiovanna Lucchini
Giovanna Lucchini
SLSu-Han Lum
Su-Han Lum
GOGiorgio Ottaviano
Giorgio Ottaviano
NBNatalia Builes
Natalia Builes
PVPaul Veys
Paul Veys
This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation–based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD.